Wanbury
NSE: WANBURY · Pharmaceuticals
Snapshot
Unlock Wanbury's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Wanbury Limited is an Indian pharmaceutical company engaged in the manufacturing and sale of active pharmaceutical ingredients (API) and finished formulations. The company operates across diverse therapeutic areas including gynecology, orthopedics, anti-diabetic, and anti-inflammatory segments.
Business Model
The company generates revenue through the production and distribution of approximately 70 branded formulations and a wide range of API products. It serves both the domestic Indian market and international markets through its export operations.
- Brand Portfolio:Approximately 70 brands
Growth Outlook
Growth is driven by the expansion of its therapeutic product portfolio and the continued scaling of its API manufacturing capabilities for both domestic and global markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety regulations from domestic and international health authorities, where non-compliance could disrupt operations.
- Input Cost Volatility. Fluctuations in the prices of raw materials and key starting materials for API production can significantly impact profit margins.
- Competitive Pressure. The pharmaceutical sector in India is highly fragmented and competitive, which may exert pressure on pricing and market share for the company's formulations.
- Export Dependency. Exposure to international markets introduces risks related to currency fluctuations, geopolitical instability, and varying regulatory standards across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Wanbury and 5,000+ companies — free.
Key Metrics
REVENUE
₹653 Cr
TTM · standalone
NET PROFIT
₹56 Cr
TTM · standalone
EPS
₹17.36
TTM · standalone
RETURN ON EQUITY
54.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
29.2%
TTM · standalone
P/E
11.4×
Q1 FY27 · standalone
EV/EBITDA
10.3x
Q1 FY27 · standalone
EBITDA MARGIN
15.2%
TTM · standalone
NET PROFIT MARGIN
2.0%
Q1 FY27 · standalone
DEBT TO EQUITY
1.5x
Q1 FY27 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
WanburyWANBURY | ₹814 Cr | 11.4× | 10.33 | 3.6% | 15.2% | 54.9% | 29.2% | -20.6% |
Anuh PharmaANUHPHR | ₹936 Cr | 24.0× | 12.93 | 9.7% | 9.2% | 13.0% | 17.7% | +3.1% |
Bafna Pharmaceuticals LimitedBAFNAPH | ₹796 Cr | 115.1× | 46.63 | -3.1% | 12.5% | 8.6% | 10.3% | +119.3% |
Kilitch Drugs (India) LimitedKILITCH | ₹775 Cr | 17.4× | 17.72 | 14.0% | 20.2% | 12.1% | 15.6% | -36.5% |
Amanta HealthcarAMANTA | ₹735 Cr | 45.8× | 14.20 | — | 21.5% | 6.7% | 9.9% | +39.7% |
Zim LaboratoriesZIMLAB | ₹715 Cr | 167.1× | 20.79 | 7.6% | 9.9% | 1.3% | 5.7% | +91.2% |
As of Q1 FY27
Financials
Wanbury
NSE: WANBURY · Pharmaceuticals
Snapshot
Unlock Wanbury's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Wanbury Limited is an Indian pharmaceutical company engaged in the manufacturing and sale of active pharmaceutical ingredients (API) and finished formulations. The company operates across diverse therapeutic areas including gynecology, orthopedics, anti-diabetic, and anti-inflammatory segments.
Business Model
The company generates revenue through the production and distribution of approximately 70 branded formulations and a wide range of API products. It serves both the domestic Indian market and international markets through its export operations.
- Brand Portfolio:Approximately 70 brands
Growth Outlook
Growth is driven by the expansion of its therapeutic product portfolio and the continued scaling of its API manufacturing capabilities for both domestic and global markets.
Key Risks
- Regulatory Compliance. The company is subject to stringent quality and safety regulations from domestic and international health authorities, where non-compliance could disrupt operations.
- Input Cost Volatility. Fluctuations in the prices of raw materials and key starting materials for API production can significantly impact profit margins.
- Competitive Pressure. The pharmaceutical sector in India is highly fragmented and competitive, which may exert pressure on pricing and market share for the company's formulations.
- Export Dependency. Exposure to international markets introduces risks related to currency fluctuations, geopolitical instability, and varying regulatory standards across different countries.
Start your research today
Unlock AI insights, financials, peers and live data on Wanbury and 5,000+ companies — free.
Key Metrics
REVENUE
₹653 Cr
TTM · standalone
NET PROFIT
₹56 Cr
TTM · standalone
EPS
₹17.36
TTM · standalone
RETURN ON EQUITY
54.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
29.2%
TTM · standalone
P/E
11.4x
Q1 FY27 · standalone
EV/EBITDA
10.3x
Q1 FY27 · standalone
EBITDA MARGIN
15.2%
TTM · standalone
NET PROFIT MARGIN
2.0%
Q1 FY27 · standalone
DEBT TO EQUITY
1.5x
Q1 FY27 · standalone
Peers · Pharmaceuticals
As of Q1 FY27